AccuShares(R) Investment Management, LLC ("AccuShares")

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AccuShares(R) Investment Management, LLC ("AccuShares") Announces a Regular and Net Income (if Applicable) Distributions, and a Corrective Distribution for Both AccuShares Spot CBOE(R) VIX(R) Up Shares and Down Shares

STAMFORD, CT --(Marketwired - July 19, 2016) - AccuShares, as sponsor of the AccuShares Trust I (formerly known as the AccuShares Commodity Trust I) (the "Trust"), today announces a Regular Distribution and, if applicable, a Net Income Distribution for AccuShares Spot CBOE VIX Up Shares ( NASDAQ : VXUP ) (the "Up Shares") and Spot CBOE VIX Down Shares ( NASDAQ : VXDN ) (the "Down Shares"). AccuShares also announces a Corrective Distribution for Up Shares and Down Shares. The terms Regular Distribution, Corrective Distribution and Net Income Distribution are defined and described in the current prospectus of the AccuShares Spot CBOE VIX Fund (the "Fund").

The relevant estimated distribution information is provided in the tables below:

Distribution Dates :

NASDAQ Ticker   Name   Ex-Date   Record Date   Distribution Payment Date
VXUP   AccuShares Spot CBOE VIX Up Shares   July 20, 2016   July 22, 2016   July 26, 2016
VXDN   AccuShares Spot CBOE VIX Down Shares   July 20, 2016   July 22, 2016   July 26, 2016

Estimated Distribution Amount Information :

NASDAQ Ticker   Name   Closing Index Value as of July 19, 2016   Post-Distribution Share Index Factor*   Post-Distribution Class Value per Share*   Net Income Distribution Amount Per Share   Regular Distribution Amount Per Share**   Corrective Distribution Amount Per Share
VXUP   AccuShares Spot CBOE VIX Up Shares   11.97   0.33416876   $4.00   $0.000000   NA   1 Down Share
VXDN   AccuShares Spot CBOE VIX Down Shares   11.97   -0.33416876   $4.00   $0.000000   0.805342 of Up Share and 0.805342 of Down Share   1 Up Share

* As defined in the Fund's prospectus. ** De minimis amount of $9.43 is being retained in the Fund.

Corrective Distribution

The Corrective Distribution will affect the class value per share of both the Up Shares and Down Shares, but it will not impact the value of a shareholder's holdings in the Fund.

More information about the Fund can be found at the Trust's website at www.accushares.com .

Investor Reassessment:

Investors wishing to maximize exposure to the index tracked by the Fund, the CBOE Volatility Index, in either direction, or investors wishing to compound gains over one or more distribution dates must invest any cash distributed, and sell any shares distributed and invest the sale proceeds thereof, in the class of shares aligned with their investment objectives.

The Fund has been designed to be utilized by investors who are prepared to reassess their holding of the Fund's shares at least as frequently as each distribution date. Investors in the Fund who wish to maintain a maximum exposure, a targeted absolute exposure, or a targeted relative exposure to the Underlying Index over multiple distribution dates should reassess their positions following all cash and share distributions, and all Fund resets relating to the Share Index Factors. The Fund will not compound investor gains or otherwise rebalance investor positions to maximize investor exposure. The Fund is designed to make Regular Distributions of cash and in some cases shares to facilitate regular distribution of investor gains and to promote a deliberate and regular reassessment by investors of their investment in the Fund.

Investors who hold shares over one or more consecutive distribution dates without reassessment of their Fund share portfolio may experience decreased exposure to the Underlying Index as well as a reduced opportunity for gain and loss.

About AccuShares:

Founded in 2011, AccuShares Investment Management, LLC, ( www.accushares.com ) develops and sponsors innovative exchange traded funds (ETFs) in key alternative asset classes, including oil and volatility. The company holds a series of technology patents that provide the basis for a more institutional approach to constructing index-based products, enhancing tracking accuracy and transparency while reducing fund costs.

Disclosures:

Neither the Trust nor the Fund is an investment company within the meaning of the Investment Company Act of 1940 and neither is subject to regulation thereunder. Although AccuShares is registered as a commodity pool operator with the Commodity Futures Trading Commission ("CFTC"), the Trust and the Fund are not subject to regulation under the Commodities Exchange Act or by the CFTC. Consequently Fund shareholders are not afforded the regulatory protections provided to investors in registered investment companies or commodity pools.

Investing in the Funds involves substantial risk and high volatility, including possible loss of principal. Shares of the Fund are intended for sophisticated, professional and institutional investors. The Fund is not intended to be used as a long-term passive investment vehicle and should be used by investors who understand the risks of the volatility market. Investors expecting the Underlying Index to decline should purchase the Fund's Down Shares, and investors expecting the Underlying Index to increase should purchase the Fund's Up Shares, to align their respective Fund investments with their respective expectations. Please read the Fund's prospectus carefully before investing. The Fund's prospectus can be obtained by clicking the link below.

http://www.accushares.com/resources/vix-fund-prospectus

The Trust is a Delaware statutory trust organized by AccuShares into separate fund series. The Fund's shares represent fractional undivided interests in and ownership of the Fund only and not any other series of the Trust or the Trust as a whole. The Fund offers its shares on a continuous basis and is listed on the NASDAQ.

Disclaimers:

The Fund is not sponsored, endorsed, sold or promoted by S&P Dow Jones Indices LLC (the "Index Provider"), Dow Jones Trademark Holdings LLC ("Dow Jones"), Standard & Poor's Financial Services LLC ("S&P"), their respective affiliates or their third party licensors (including The Chicago Board Options Exchange Incorporated ("CBOE")) and none of such parties make any representation or warranty, express or implied, regarding the advisability of investing in securities generally or in the Fund particularly, or the ability of the Underlying Index or any related indices or sub-indices to track the appropriate market performance, or as to the results to be obtained by the Trust, the Fund, the Fund's shareholders or any other person or entity from use of the Underlying Index or any data included therein. None of such parties have any liability for any errors, omissions, or interruptions in the Underlying Index or such data, and the Index Provider and CBOE do not guarantee the accuracy or the completeness of the Underlying Index or such data. Neither the Index Provider nor CBOE make any express or implied warranties, and expressly disclaim all warranties of merchantability or fitness for a particular purpose or use with respect to the Underlying Index or such data. Without limiting any of the foregoing, the Index Provider, Dow Jones, S&P, CBOE, their affiliates and third party licensors expressly disclaim any and all liability for any special, punitive, indirect, or consequential damages (including lost profits), even if notified of the possibility of such damages.

The only relationship of the Index Provider, CBOE, their affiliates or their third party licensors to AccuShares, the trustee of the Trust (the "Trustee"), the Trust or the Fund is the licensing of certain trademarks, trade names and service marks and of the Underlying Index, which is constructed, calculated and published by CBOE, and has been licensed by the Index Provider, without regard to AccuShares, the Trustee, the Trust or the Fund. Neither AccuShares, nor the Trustee, nor the Trust, nor the Fund has any contractual relationship or other arrangement with CBOE with respect to the use of the Underlying Index and related intellectual property. Instead, the rights of AccuShares, the Trust and the Fund to utilize the Underlying Index and related intellectual property is derivative of the rights of the Index Provider under its agreement with CBOE. CBOE has no obligation to take the needs of AccuShares, the Trustee, the Trust, the Fund or the Fund's shareholders into consideration in determining, composing or calculating the Underlying Index.

Neither the Index Provider, CBOE, nor any of their respective affiliates or third party licensors is responsible for or has participated in the determination of the timing, price or quality of the shares issued by the Fund or in the determination or calculation of the equation by which the shares are to be converted into cash. Neither the Index Provider, CBOE, nor any of their respective affiliates or third party licensors shall have any obligation or liability, including, without limitation, to Fund investors, in connection with the administration, marketing or trading of the Fund.

The Underlying Index is a product of CBOE, which is licensed by the Index Provider or its affiliates to AccuShares in connection with the operation of the Fund. Standard & Poor's ® and S&P ® are registered trademarks of S&P; Dow Jones ® is a registered trademark of Dow Jones; CBOE ® , Chicago Board Options Exchange ® , CBOE Volatility Index ® and VIX ® are registered trademarks of CBOE; and these trademarks have been licensed for use by the Index Provider and sublicensed for certain purposes by AccuShares. AccuShares ™ is a trademark of AccuShares Holdings LLC.

Foreside Fund Services, LLC Marketing Agent

AccuShares Investor Service Center 1-855-286-7866 info@accushares.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 562

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 88

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 395

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 193

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 437

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 67

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 116

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 619

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 461

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 573

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading

Top 5 Most Recently Viewed Articles

Siemens Expands Presence with New Facility in Tech City

Updated Category News Views 643

Siemens Launches New Facility at San Felasco Tech City Siemens is excited to reveal a major development in its journey toward innovation and sustainability. The company will be setting up a 6,500 square foot facility at San Felasco Tech City, a top-notch business park that prioritizes cutting-edge technologies along with environmental stewardship. About San Felasco Tech...

Continue Reading
Fitting Futures: A Transformative Journey in Student Support

Updated Category News Views 137

Fitting Futures: A New Chapter for Student Support In a refreshing turn of events, a nonprofit dedicated to empowering students has undergone a remarkable transformation. The White Cane Foundation, known for its unwavering support to students in need, has rebranded itself as Fitting Futures. This name change signifies a heartfelt commitment to ensuring that every student...

Continue Reading
Gaming and Leisure Properties Expands with New Casino Venture

Updated Category News Views 266

Gaming and Leisure Properties Seizes New Opportunities Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) is making waves in the gaming and hospitality industry with its recent agreement to acquire land for the much-anticipated Live! Casino and Hotel Virginia. This exciting project, which involves a joint venture with The Cordish Companies and Bruce Smith Enterprise,...

Continue Reading
Exploring the Expanding Polypropylene Compounds Market

Updated Category News Views 149

Expansion of the Polypropylene Compounds Market As the world progresses towards more sustainable and lightweight materials, the polypropylene compounds market is projected to reach a staggering USD 24.8 billion by 2030. This growth, which is rooted in a compound annual growth rate (CAGR) of 6.2%, is largely driven by the increasing need for lightweight materials in...

Continue Reading
Pimax Unveils Cutting-Edge VR Headsets at CES 2026 Event

Updated Category News Views 250

Exciting Innovations in VR Technology at CES 2026 LAS VEGAS, January 2026 – Pimax has made headlines at the Consumer Electronics Show (CES) this year with the release of its next-gen lineup of PCVR headsets. The company has showcased its latest model, the Crystal Super Micro-OLED, alongside the Dream Air and Dream Air SE. These headsets highlight Pimax's dedication to...

Continue Reading